Want to see HK:1931 full AI Analyst Report?
IVD Medical Holding Limited (1931) AI Stock Analysis
IVD Medical Holding Limited
(HKEX:1931)
Primarily impacted by poor financial performance in 2025 with declining profits, margins, and negative cash flows. Bearish technical signals with price below moving averages and negative MACD reinforce downside risks, while negative valuation metrics add to concerns.
IVD Medical Holding Limited (1931) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 568.56M
- Dividend Yield
- ―
- Average Volume (3M)
- 249.75K
- Price to Earnings (P/E)
- -6.5
- Beta (1Y)
- 0.87
- Revenue Growth
- -2.55%
- EPS Growth
- -145.60%
- Country
- Hong Kong
- Employees
- 910
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
IVD Medical Holding Limited Business Overview & Revenue Model
Company Description
ETHK Labs Inc., formerly IVD Medical Holding Ltd, is an investment holding company that distributes In vitro diagnostic (IVD) products in Mainland China and internationally. The company operates through three segments: Distribution Business, After-sa...
IVD Medical Holding Limited Financial Statement Overview
Summary
IVD Medical Holding's 2025 results show sharp drops in revenue to 2.75B, net margins to 1.2%, and deeply negative cash flows at -919M, despite prior asset growth, highlighting operational and leverage risks.
Income Statement
35NegativeBalance Sheet
45NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.91B | 2.82B | 3.16B | 3.09B | 2.75B | 2.73B |
| Gross Profit | 584.46M | 566.37M | 751.17M | 671.70M | 608.14M | 566.27M |
| EBITDA | 159.80M | 235.09M | 475.96M | 397.93M | 349.66M | 297.86M |
| Net Income | -74.76M | 34.93M | 260.42M | 238.16M | 210.00M | 174.54M |
Balance Sheet | ||||||
| Total Assets | 14.77B | 5.94B | 5.52B | 4.79B | 4.31B | 4.37B |
| Cash, Cash Equivalents and Short-Term Investments | 1.10B | 551.05M | 1.86B | 1.24B | 1.04B | 841.78M |
| Total Debt | 2.60B | 1.93B | 755.97M | 344.32M | 349.92M | 427.65M |
| Total Liabilities | 4.46B | 2.93B | 1.76B | 1.40B | 1.16B | 1.37B |
| Stockholders Equity | 2.81B | 2.95B | 3.71B | 3.34B | 3.15B | 2.98B |
Cash Flow | ||||||
| Free Cash Flow | -1.34B | -1.01B | 88.69M | 251.92M | 215.39M | 137.88M |
| Operating Cash Flow | -1.23B | -918.89M | 140.29M | 292.42M | 249.67M | 163.11M |
| Investing Cash Flow | -1.08B | -1.35B | -57.80M | -77.58M | 60.54M | -27.88M |
| Financing Cash Flow | 693.93M | 831.04M | 395.13M | -19.45M | -191.29M | -66.29M |
IVD Medical Holding Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1931, the sentiment is Negative. The current price of 0.35 is below the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.46, and below the 200-day MA of 0.88, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 40.02 is Neutral, neither overbought nor oversold. The STOCH value of 24.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1931.
IVD Medical Holding Limited Peers Comparison
Overall Rating
HK:219281Outperform
HK:109965Neutral
HK:260758Neutral
HK:228947Neutral- HK:193138Underperform
HK:067337Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2192 | 81Outperform | HKD 4.67B | 11.63 | 7.05% | 4.98% | 6.47% | 8.10% |
| HK:1099 | 65Neutral | HKD 50.52B | 6.11 | 8.33% | 4.88% | 2.78% | 7.71% |
| HK:2607 | 58Neutral | HKD 64.52B | 11.88 | 6.64% | 5.88% | 9.12% | -3.22% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2289 | 47Neutral | HKD 592.92M | 10.83 | 7.70% | 6.26% | 14.25% | 0.83% |
| HK:1931 | 38Underperform | HKD 575.63M | -6.46 | -2.60% | ― | -2.55% | -145.60% |
| HK:0673 | 37Underperform | HKD 360.66M | -5.29 | -273.18% | ― | 5.52% | 56.54% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1931 | IVD Medical Holding Limited | 0.35 | -5.93 | -94.35% | |
| HK:0673 | China Health Group | 0.26 | -0.36 | -58.06% | |
| HK:2607 | Shanghai Pharmaceuticals Holding Co Class H | 11.11 | -0.06 | -0.53% | |
| HK:1099 | Sinopharm Group Co Class H | 16.19 | -2.17 | -11.84% | |
| HK:2192 | Medlive Technology Co., Ltd. | 6.30 | -4.03 | -38.99% | |
| HK:2289 | Charmacy Pharmaceutical Co., Ltd. Class H | 5.49 | 0.38 | 7.46% |
IVD Medical Holding Limited Corporate Events
ETHK Labs Halts Key Digital Asset Initiatives Amid Regulatory Reassessment
ETHK Labs has suspended further development of its proposed digital-asset exchange, RWA platform and IVDD stablecoin after reassessing regulatory requirements, feasibility and Mainland China’s discouraging stance on RWA, confirming it is not cu...
ETHK Labs Swings to Interim Loss Despite Revenue Boost from B-Soft Acquisition
ETHK Labs Inc. reported a 6.6% rise in revenue to RMB1.35 billion for the six months ended 30 June 2026, largely due to the consolidation of B-Soft Co., Ltd.’s results following its acquisition. Despite the top-line growth, the group swung to a...
ETHK Labs Flags Interim Loss on Rising Costs and Credit Provisions
ETHK Labs Inc. has warned that it expects to swing to a loss of up to RMB74 million for the six months ended 30 June 2026, compared with a profit of about RMB39.1 million a year earlier, marking a deterioration of roughly RMB113.1 million. The revers...
ETHK Labs Sets Board Meeting to Review Interim Results and Dividend
ETHK Labs Inc. has scheduled a board meeting for 31 August 2026 in Hong Kong to review and approve the group’s interim results for the six months ended 30 June 2026, and to consider the declaration of any interim dividend. The agenda indicates...
ETHK Labs Clarifies EGM Vote, Narrowly Approves Share Transfer and Voting Deal
ETHK Labs Inc. has issued a clarification regarding the poll results from its extraordinary general meeting held on 27 July 2026, after discovering misstatements in the previously published voting figures. The corrected results show that shareholders...
ETHK Labs Shareholders Narrowly Approve Share Transfer and Voting Rights Deals
Shareholders of ETHK Labs Inc. narrowly approved a share transfer agreement at an extraordinary general meeting held on 27 July 2026, with 51.34% of votes cast in favor and 48.66% against. The deal involves the transfer of shares from vendor Mr. Ge H...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026